Retrograde Lymphatic Spread of Esophageal Cancer
A Case Report

Hisashi Oshiro, MD, PhD, Yoshiaki Osaka, MD, PhD, Shingo Tachibana, MD, PhD, Takaya Aoki, MD, PhD, Takayoshi Tsuchiya, MD, PhD, and Toshitaka Nagao, MD, PhD

Abstract: The concept of the retrograde lymphatic spread of cancer cells appears to account for a subset of the essential mechanisms of cancer metastasis in various organs. However, no adequate data currently exist to illustrate the pathology of the retrograde lymphatic metastasis of cancer cells in human bodies. To shed light on this phenomenon, we report a case of a 63-year-old Japanese man who underwent an esophagectomy and lymph node dissection for early-stage esophageal cancer.

The patient’s clinical information was evaluated by board-certified surgeons and internists. Surgically excised materials were histopathologically evaluated by attending pathologists.

Postoperative pathological examination revealed that the patient’s tumor was a well-differentiated squamous cell carcinoma with negative surgical margins (T1N0M0, stage I). Apart from the primary lesion, a single lymphatic vessel invasion was found between the lamina propria and lamina muscularis of the esophagus where intralymphatic cancer cells had spread against the direction of backflow prevention valves and skipped beyond these valves without destroying them.

The present case demonstrated that the retrograde lymphatic spread of cancer cells can occur in valve-equipped lymphatic vessels. Our study may not only provide a scientific basis for the concept of retrograde lymphatic metastasis but also explain a portion of the complexities associated with the lymphogenous metastasis of esophageal cancer.

METHODS

Written informed consent for this case study was obtained from the patient. The patient’s clinical information was evaluated by board-certified surgeons (YO and ST) and internists (TA and TT). Surgically excised materials were immediately fixed in 20% neutral buffered formalin for routine histological examination and evaluated by attending pathologists (HO and TN). Immunohistochemistry was performed using a D2-40 antibody (D2-40; Nichirei Bioscience; Tokyo, Japan), a detection kit (Histofine Simple Stain MAX PO, MULTI; Nichirei Bioscience), and an autostainer (Histostainer; Nichirei Bioscience) according to the manufacturer’s instruction.

RESULTS

Clinical Findings

A 63-year-old Japanese man was referred to our hospital for a detailed examination and treatment of esophageal cancer that had been detected during his health checkup. His history was unremarkable except for hypertension, which had been well controlled by an antihypertensive drug. He had been a smoker (Brinkman index = 1290) and had consumed approximately 34–54 g of alcohol per day for 43 years. His mother had suffered from gastric cancer, and his elderly brother had suffered from bladder cancer. No metastatic lesions were detected in his preoperative work-up, which consisted of systemic

INTRODUCTION

Lymph node (LN) metastasis is an important prognostic predictor for esophageal squamous cell carcinoma. The bidirectional or skip nodal spread of cancer cells is thought to be a key feature of lymphatic metastasis in patients with thoracic esophageal squamous cell carcinoma. Thus, it is important to discover the mechanisms of the lymphatic metastasis of esophageal cancer.
computed tomography (Figure 1) and 18F-fluorodeoxyglucose positron emission tomography. The patient underwent subtotal esophagectomy and LN dissection with assistance from a da Vinci surgical system followed by a thoracoscopy and anastomosis of the stomach to the cervical esophagus via the posterior portion of the mediastinum, with the gastric tube reconstructed by hand-assisted laparoscopic surgery. His postoperative course was uneventful. He has been regularly followed without adjuvant therapy and has remained free from disease recurrence for 38 months since his operation.

**Pathological Findings**

After the operation, histopathological examination was performed on the excised esophagus and dissected LNs by total segmentation, and a final diagnosis of the lesion was generated (Figure 2). This lesion was a single tumor 47 × 38 mm in size located in the middle to the lower thoracic portion of the esophagus. The tumor was a superficial (0 – Ip + Iic type), well-differentiated squamous cell carcinoma with invasion into 2/3 of the depth of the submucosal layer (500 μm) from the inferior border of the muscularis mucosae, and it had negative surgical margins, no intramural metastasis and no LN metastases (pN0; #1: right cardiac LNs [0/3]; #3: LNs along the lesser curvature [0/9]; #7: LNs along the left gastric artery [0/3]; #101L: left cervical paraeosophageal LN [0/5]; #105: upper thoracic paraeosophageal LNs [0/5]; #106recL: left recurrent nerve LNs [0/3]; #106dbL: left tracheobronchial LNs [0/0]; #107: subcarinal LNs [0/4]; #108: middle thoracic paraeosophageal LNs [0/2]; #109L: left main bronchus LNs [0/2]; #109R: right main bronchus LNs [0/8]; #110: lower thoracic paraeosophageal LNs [0/1]; and #112: posterior mediastinal LNs [0/0]). The tumor was categorized as T1bN0M0 and stage I using the Japanese classification of esophageal cancer. Venous invasion was confirmed in 1 small vein in the esophagus by Elastica-van Gieson staining. In particular, distant from the primary lesion, a single lymphatic vessel running along the lamina muscularis had been invaded by cancer cells (Figure 3). The nature of lymphatics was immunohistochemically confirmed using a

**FIGURE 1.** A contrast enhanced computed tomographic image of the thoracic organs demonstrates no remarkable changes, except for slight thickening of the wall in the lower thoracic portion of the esophagus (arrow).

**FIGURE 2.** (Pathological findings for the examined esophageal cancer. A: A gross image depicts a superficial (0 – Ip + Iic type) single tumor 47 × 38 mm in size located in the middle to the lower thoracic portion of the esophagus (arrowheads). B: A low-power photomicrograph reveals a primary lesion (arrowheads) and an area of retrograde lymphatic invasion distant from the primary lesion (rectangle) (hematoxylin and eosin stain). C: A high-power photomicrograph illustrates the primary lesion and features indicating the invasion of well-differentiated squamous cell carcinoma into the submucosal layer (hematoxylin and eosin stain).
D2-40 antibody. In this lymphatic vessel, 2 cancer cell clusters were observed. Notably, intralymphatic cancer cells had spread against the direction of backflow prevention valves. Moreover, serial tissue sections revealed that intralymphatic cancer cells had skipped beyond these valves without morphological destruction of the valves. The lymphatic lumen was dilated, and the cancer cell clusters appeared to be partially attached to the endothelium. The distance from the primary lesion to the distal margin of the intralymphatic cancer cell cluster was approximately 5 mm. The upward lymphatic vessel located after the cancer cell cluster that could be tracked by the tissue sections was approximately 100 mm in length, and it became smaller in diameter, accompanied by a closed lymphatic valve, and was no longer invaded by cancer cells.

**DISCUSSION**

In the present case, one could consider the possibility of the anterograde lymphatic spread of cancer cells from other lymphatics. However, this possibility was excluded for the following reasons: the esophagus was histopathologically inspected by total segmentation, and only a single lymphatic vessel had been invaded by cancer cells; there was no LN metastasis; and no neoadjuvant therapy was administered to the patient. Moreover, the possibility of the artificial implantation of cancer cells was excluded for the following reasons: during the operation, surgeons gently excised the esophagus without strong pressure and after formalin fixation, pathologists gently cut the esophagus with a disposable blade without strong pressure, and the blade surface was cleaned with clear gauze following each cut.

The mechanisms of lymphatic valve opening and closure can be depicted by considering the following fluid pressures at different locations around a valve: the pressure in front of the valve (P1); the pressure in the funnel-shaped space between valve faces (P2); and the pressure in the pocket (P3) (Figure 4). If \( P1 > P2 > P3 \), the valve is open, and fluid flows in an anterograde direction (there are several other possibilities as well, including \( P1 > P2 = P3 \)). If \( P1 = P2 < P3 \), the valve is closed. If \( P1 = P2 = P3 \), the stoppage of fluid flow occurs. Moreover, when \( P1 = P2 = P3 \), it is possible for particles, such as cancer cells, in the fluid to move through the valve by random Brownian diffusion. If \( P1 < P2 = P3 \), the valve is open, and fluid flows in a retrograde direction. Thus, the retrograde lymphatic spread of cancer cells can occur if \( P3 \) increases such that regurgitation of the valve occurs even if this regurgitation is not continuous.

The mechanisms of the retrograde lymphatic spread of cancer cells in the current case can be explained by the following phenomena: an increase in downstream intralymphatic pressure caused by lymphatic obstruction following cancer invasion or by an extrinsic lymph pump that depends on adjacent tissue movements, such as swallowing, esophageal peristalsis, arteriolar vasomotion, arteriolar pulsation, or respiration; contractile dysfunction of the lymphatic wall caused by a tumor thrombus or by physiologically active substances, such as VEGF-C, which may have been released by cancer cells or lymphatic endothelial cells; and intermittent regurgitation of the lymphatic valve caused by lymphatic ectasia or by the adhesion of cancer cells to lymphatic endothelial cells, presumably via adhesion-related molecules, such as ICAM-1, which have been expressed by either type of cell.

The anatomical distribution in the middle and posterior mediastinal lymphatics is complex. Characteristically, lymphatics originating from the lower thoracic esophagus share...
with lymphatics originating from the pulmonary ligament, which has lymphatic stomata and a rich lymphatic network. These lymphatics connect with LNs of the tracheal bifurcation and with celiac LNs to form lymphatic chains. In addition, lymphatics originating from the thoracic esophagus frequently drain into the thoracic duct directly without intervening LNs. Notably, the human thoracic duct has multiple collateral branches where anterograde 1-leaflet valves, retrograde 1-leaflet valves or oppositely arrayed 2-leaflet valves are frequently present, allowing for bidirectional lymph flow and accommodating the flow rate of the thoracic duct based on physiological or pathological conditions. These characteristics can account for part of the basis of bidirectional or skip nodal metastasis in esophageal cancer.

Recent experimental studies have demonstrated that the rerouting of lymph flow is a key feature in the development of lymphatic metastases. Larger metastases within the sentinel LN can obstruct lymphatic drainage, rerouting lymph flow toward another LN that is metastasis-free, which can lead to a false-negative sentinel LN. At a later stage, this LN accepts cancer cells via rerouted flow from the metastatic sentinel LN. However, the means by which lymphatic rerouting occurs remain incompletely elucidated. Certain investigators have speculated that the rerouting of lymph flow involves anterograde travel via newly generated bypassing and collateral lymphatics. In contrast, the present case study suggests that such rerouting can also occur via pre-existing lymphatic vessels in a retrograde manner.

There has been keen interest concerning the effect of extended lymphadenectomy and the usefulness of sentinel node navigation surgery for esophageal cancers among research-oriented clinical investigators. However, different procedures under different conditions by various institutions often make a comparison of studies difficult, leading to indefinite conclusions. We have more to accomplish before standardization of clinical practices against the lymphatic system. Further elucidation of human lymphatic pathology will help to develop and standardize better therapeutic strategies in esophageal cancers.

In summary, our study demonstrated that the retrograde lymphatic spread of cancer cells occurs against the direction of lymphatic valves without structural destruction of these valves. The present study may not only provide a scientific basis for the concept of retrograde lymphatic metastasis but also explain a portion of the complexities associated with the lymphogenous metastasis of esophageal cancer.

REFERENCES
1. Akiyama H, Tsurumaru M, Udagawa H, et al. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364–372.
2. Ding X, Zhang J, Li B, et al. A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy. Br J Radiol. 2012;85:e1110–e1119.
3. Debois JM. *TsNxM1. The Anatomy and Clinics of Metastatic Cancer*. New York: Kluwer Academic Publisher; 2002.

4. Bussani R, De-Giorgio F, Abbate A, et al. Cardiac metastases. *J Clin Pathol.* 2007;60:27–34.

5. Leijte JA, van der Ploeg IM, Valdes Olmos RA, et al. Visualization of tumor blockage and rerouting of lymphatic drainage in penile cancer patients by use of SPECT/CT. *J Nucl Med.* 2009;50:364–367.

6. Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. *Esophagus.* 2015;12:1–30.

7. Schmid-Schonbein GW. Microlymphatics and lymph flow. *Physiol Rev.* 1990;70:97–1028.

8. Karaman S, Detmar M. Mechanisms of lymphatic metastasis. *J Clin Invest.* 2014;124:922–928.

9. Tullavardhana T, Akranurakkul P, Ungkitphaiboon W, et al. Vascular endothelial growth factor-C expression as a biomarker of poor prognosis in esophageal squamous cell carcinoma: a meta-analysis. *Oncol Res Treat.* 2015;38:110–114.

10. Rockett JC, Darnton SJ, Crocker J, et al. Lymphocyte infiltration in oesophageal carcinoma: lack of correlation with MHC antigens, ICAM-1, and tumour stage and grade. *J Clin Pathol.* 1996;49:264–267.

11. Kawai Y, Kaidoh M, Yokoyama Y, et al. Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes. *Cancer Sci.* 2009;100:419–428.

12. Murakami G. Mediastinum. In: Ohtani O, Kato S, Uchino S, eds. *Lymphatics*. Niigata: Nishimura-shoten; 1997:266–274.

13. Murakami G, Sato I, Shimada K, et al. Direct lymphatic drainage from the esophagus into the thoracic duct. *Surg Radiol Anat.* 1994;16:399–407.

14. Oshiro H, Miura M, Iobe H, et al. Lymphatic stomata in the adult human pulmonary ligament. *Lymphat Res Biol.* 2015;13:137–145.

15. Riquet M. Lung cancer and lymph drainage. *Cancer Radiother.* 2007;11:4–10.

16. Riquet M, Le Pimpec Barthes F, Soulamas R, et al. Thoracic duct tributaries from intrathoracic organs. *Ann Thorac Surg.* 2002;73:892–898.

17. Saito H, Sato T, Miyazaki M. Extramural lymphatic drainage from the thoracic esophagus based on minute cadaveric dissections: fundamentals for the sentinel node navigation surgery for the thoracic esophageal cancers. *Surg Radiol Anat.* 2007;29:531–542.

18. Magari S. The thoracic duct. In: Ohtani O, Kato S, Uchino S, eds. *Lymphatics*. Niigata: Nishimura-shoten; 1997:296–301.

19. Magari S, Uno Y, Otsuki Y, et al. Anatomic study of branches and valves of the thoracic duct in man, with special reference to the inverted valves. *Myakkangaku.* 1986;26:545–555.

20. Proulx ST, Luciani P, Christiansen A, et al. Use of a PEG-conjugated bright near-infrared dye for functional imaging of rerouting of tumor lymphatic drainage after sentinel lymph node metastasis. *Biomaterials.* 2013;34:5128–5137.

21. Nathanson SD, Mahan M. Sentinel lymph node pressure in breast cancer. *Ann Surg Oncol.* 2011;18:3791–3796.

22. Ma GW, Situ DR, Ma QL, et al. Three-field vs two-field lymph node dissection for esophageal cancer: a meta-analysis. *World J Gastroenterol.* 2014;20:18022–18030.

23. Merkow RP, Bilimoria KY, Keswani RN, et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. *J Natl Cancer Inst.* 2014;106:pii:dju133.

24. Koen Talsma A, Shapiro J, Looman CW, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. *Ann Surg.* 2014;260:786–792.

25. Nagaraja V, Eslick GD, Cox MR. Sentinel lymph node in oesophageal cancer: a systematic review and meta-analysis. *J Gastrointest Oncol.* 2014;5:127–141.

26. Dabbagh Kakhki VR, Bagheri R, Tehranian S, et al. Accuracy of sentinel node biopsy in esophageal carcinoma: a systematic review and meta-analysis of the pertinent literature. *Surg Today.* 2014;44:607–619.

27. Pech S O. Nodes or no nodes? The lymph node metastasis risk of T1 esophageal cancer revisited. *J Natl Cancer Inst.* 2014;106:pii:dju174.